EyePoint Pharmaceuticals, Inc.

NASDAQ:EYPT

Biotechnology

Healthcare
$2.99 +1.98%

+$0.26 today

Market cap
$250.69M
Beta
1.75
P/E (TTM)
-4.2
EPS (TTM)
-$3.16
52W Low $7.94High $19.11

Volume 2.75M

Average 0.95M

EYPT Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

EyePoint Pharmaceuticals, Inc.NASDAQ: EYPT

Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Free cash flow grows, but more slowly than its trailing trend

Q1 FY2026 free cash flow of $81.55M (cash outflow) rose 52.7% year over year, behind the +79.5% change in trailing-twelve-month free cash flow. Sequentially, it rose 23.5% from the prior quarter. Over 3 fiscal years it compounded at +53.6% a year.

Context

  • Free cash flow amounted to 775.8% of revenue in FY2025, up 474.8 pp from a year earlier.
  • Free cash flow grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +52.7% toward the trailing-twelve-month pace of +79.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$81.55M+23.5% QoQ
Last fiscal yearDec 2025
-$243.39M+86.8% YoY
LTMMar 2026
-$271.54M+79.5% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+52.7%——
1 year+86.8%——
3-year CAGR+53.6%——
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
(243.39M) USD
Year-over-year change
-86.8%

Free Cash Flow vs competitors

How EYPT compares with its peers on the latest reported figures

  • EYPT's LTM Mar 2026 free cash flow of $271.54M is the 2nd largest of the 11 companies compared; the peer median is $111.77M.
  • Its year-over-year change of +79.5% is the 2nd highest of 11, against a peer median of +11.9%.
  • Free cash flow amounts to 3565.9% of revenue for EYPT, versus a peer median of 117.9%.
EYPT Competitors Peer median
Free Cash Flow for EYPT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$369.81M +253.2%+15.3%52.7%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$271.54M +79.5%+53.6%3565.9%
KODKodiak Sciences Inc.LTM Sep 2026$172.81M +35.8%-18.7%—
PRMEPrime Medicine, Inc.LTM Mar 2026$158.74M +42.5%+4.1%3935.1%
TNGXTango Therapeutics, Inc.LTM Sep 2026$150.39M +2.5%+6.2%—
PROKProKidney Corp.LTM Mar 2026$150.06M -0.6%+19.7%16879.1%
BCAXBicara Therapeutics Inc. Common StockLTM Mar 2026$116.58M +32.0%+49.2%—
SVRASavara Inc.LTM Mar 2026$106.97M +11.8%+43.0%—
KURAKura Oncology, Inc.LTM Mar 2026$84.46M -176.4%-13.9%117.9%
SEPNSepterna, Inc.LTM Sep 2026$77.59M -175.2%—80.6%
RZLTRezolute, Inc.LTM Mar 2026$73.48M +12.0%+20.4%—
Peer median (excluding EYPT) $111.77M+11.9%+15.3%117.9%

Competitors are the stored peer set for EYPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(58.42M)(102.25M)(70.8M)(130.87M)(231.96M)
Depreciation & Amortization2.77M2.45M464K1.54M2.31M
Deferred Income Tax(787K)083K90K279K
Stock-Based Compensation7.45M14.18M12.06M36.74M27.87M
Change in Working Capital(1.74M)(3.02M)58.88M(27.77M)(33.78M)
Accounts Receivables(10.6M)(2.66M)14.43M(244K)(10.67M)
Inventory1.35M(760K)(1.55M)1.6M492K
Accounts Payables8.48M1.2M1.52M5.73M4.68M
Other Working Capital(959K)(799K)44.48M(34.86M)(28.28M)
Other Non-Cash Items628K23.65M1.18M(5.95M)(4.83M)
Operating Cash Flow(50.1M)(65.01M)1.88M(126.23M)(240.11M)
Capital Expenditures(156K)(2.15M)(3.48M)(4.05M)(3.28M)
Acquisitions (Net)0(558K)(168K)0155K
Purchases of Investments(32.97M)(139.12M)(55.12M)(398.3M)(252.02M)
Sales of Investments0124M55.28M177.05M318.9M
Other Investing Activities0558K168K5.95M4.83M
Investing Cash Flow(33.12M)(17.27M)(3.32M)(219.36M)68.58M
Debt Repayment(146K)2.1M(40.51M)(105K)(105K)
Common Stock Issued216.83M395K226.17M163.31M175.14M
Common Stock Repurchased0(295K)000
Dividends Paid00000
Other Financing Activities223K(3.19M)1.41M813K(1.39M)
Financing Cash Flow216.9M(690K)187.07M164.02M173.65M
Effect of Forex Changes00000
Net Change in Cash133.68M(82.96M)185.63M(181.56M)2.12M
Free Cash Flow(50.25M)(67.16M)(1.61M)(130.28M)(243.39M)

EyePoint Pharmaceuticals, Inc.

NASDAQ:EYPT

Intrinsic Alpha fair value

Locked

Current Price

$2.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.